UCB SA, of Brussels, Belgium, reported top-line phase III data showing that brivaracetam reduced partial-onset seizure frequency and improved responder rates, both with statistical significance vs. placebo, when used as an adjunctive treatment in adult focal epilepsy patients with partial-onset seizures not fully controlled despite treatment with one or two concomitant antiepileptic drugs.